Allergy/Asthma News

BOSTON — Physicians should be prepared to bust some myths during discussions with families about food allergy testing, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The FDA has proposed an order for the removal of oral phenylephrine as an active ingredient from over-the-counter monograph drug products for relieving nasal congestion, according to an administration press release.

Finding an allergist that accepts Medicaid may be contributing to a lack of access to allergy-related health care, according to a study published in The American Journal of Managed Care.

As the patient demand for health care grows, so does the need for more physician assistants in medicine. However, a lack of formal training in allergy, limited resources, patient bias and improper utilization can hinder this effort.

BOSTON — Patients with chronic inducible urticaria saw improvements in itch and wheals with barzolvolimab in 12 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Students and faculty from the University of Maryland, Baltimore, worked together in an innovative pilot course that led them to document a CSX coal terminal’s impact on air pollution on the Curtis Bay neighborhood.

ORLANDO — A need for allergy labeling, disparities in epinephrine access and knowledge gaps were found among Head Start centers, according to an abstract presented at the American Academy of Pediatrics National Conference & Exhibition.

BOSTON — Patients with moderate to severe atopic dermatitis experienced relief with lebrikizumab for 52 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.